Safety and efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary Sjogren's syndrome: A phase 2, randomised, placebo-controlled 68-week study

X. Mariette; C. Baldini; F. Barone; H. Bootsma; K. Clark; S. De Vita; K. Lerang; P. Mistry; F. Morin; R. Punwaney; R. Seror; P. L. Van Daele; A. Van Maurik; N. Wisniacki; D. Roth

doi:10.1136/annrheumdis-2021-eular.2170

Safety and efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary Sjogren's syndrome: A phase 2, randomised, placebo-controlled 68-week study

X. Mariette
, C. Baldini
, F. Barone
, H. Bootsma
, K. Clark
, S. De Vita
, K. Lerang
, P. Mistry
, F. Morin
, R. Punwaney
, R. Seror
, P. L. Van Daele
, A. Van Maurik
, N. Wisniacki
, D. Roth

Translational Immunology Groningen (TRIGR)

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	78-79
Number of pages	2
Journal	Annals of the Rheumatic Diseases
Volume	80
DOIs	https://doi.org/10.1136/annrheumdis-2021-eular.2170
Publication status	Published - Jun-2021
Event	Annual European Congress of Rheumatology (EULAR) - Duration: 2-Jun-2021 → 5-Jun-2021

Access to Document

10.1136/annrheumdis-2021-eular.2170

Handle.net

Persistent link

Cite this

Mariette, X., Baldini, C., Barone, F., Bootsma, H., Clark, K., De Vita, S., Lerang, K., Mistry, P., Morin, F., Punwaney, R., Seror, R., Van Daele, P. L., Van Maurik, A., Wisniacki, N., & Roth, D. (2021). Safety and efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary Sjogren's syndrome: A phase 2, randomised, placebo-controlled 68-week study. Annals of the Rheumatic Diseases, 80, 78-79. https://doi.org/10.1136/annrheumdis-2021-eular.2170

@article{487b352451eb411bba207fc104f2dbd1,

title = "Safety and efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary Sjogren's syndrome: A phase 2, randomised, placebo-controlled 68-week study",

author = "X. Mariette and C. Baldini and F. Barone and H. Bootsma and K. Clark and \{De Vita\}, S. and K. Lerang and P. Mistry and F. Morin and R. Punwaney and R. Seror and \{Van Daele\}, \{P. L.\} and \{Van Maurik\}, A. and N. Wisniacki and D. Roth",

year = "2021",

month = jun,

doi = "10.1136/annrheumdis-2021-eular.2170",

language = "English",

volume = "80",

pages = "78--79",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

note = "Annual European Congress of Rheumatology (EULAR) ; Conference date: 02-06-2021 Through 05-06-2021",

}

Mariette, X, Baldini, C, Barone, F, Bootsma, H, Clark, K, De Vita, S, Lerang, K, Mistry, P, Morin, F, Punwaney, R, Seror, R, Van Daele, PL, Van Maurik, A, Wisniacki, N & Roth, D 2021, 'Safety and efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary Sjogren's syndrome: A phase 2, randomised, placebo-controlled 68-week study', Annals of the Rheumatic Diseases, vol. 80, pp. 78-79. https://doi.org/10.1136/annrheumdis-2021-eular.2170

Safety and efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary Sjogren's syndrome: A phase 2, randomised, placebo-controlled 68-week study. / Mariette, X.; Baldini, C.; Barone, F. et al.
In: Annals of the Rheumatic Diseases, Vol. 80, 06.2021, p. 78-79.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - Safety and efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary Sjogren's syndrome

T2 - Annual European Congress of Rheumatology (EULAR)

AU - Mariette, X.

AU - Baldini, C.

AU - Barone, F.

AU - Bootsma, H.

AU - Clark, K.

AU - De Vita, S.

AU - Lerang, K.

AU - Mistry, P.

AU - Morin, F.

AU - Punwaney, R.

AU - Seror, R.

AU - Van Daele, P. L.

AU - Van Maurik, A.

AU - Wisniacki, N.

AU - Roth, D.

PY - 2021/6

Y1 - 2021/6

U2 - 10.1136/annrheumdis-2021-eular.2170

DO - 10.1136/annrheumdis-2021-eular.2170

M3 - Meeting Abstract

SN - 0003-4967

VL - 80

SP - 78

EP - 79

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

Y2 - 2 June 2021 through 5 June 2021

ER -